Assess whether the primary endpoint will survive FDA scrutiny after a CRL

SITUATION RWE evidence-strategy director is responsible for the primary endpoint will in a company, using a CMC site change mid-review with inspection-readiness findings at a CMO as the only working extract. A CRL citing manufacturing, not efficacy is what reset the timeline for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Inspection-readiness findings at a CMO reads as Proceed under protocol once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population. 2. Inspection-readiness findings at a CMO is closer to Pause the pathway after a CRL citing manufacturing, not efficacy; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in inspection-readiness findings at a CMO for RWE evidence-strategy director in a company with a CMC site change mid-review. 4. Inspection-readiness findings at a CMO is missing the fact RWE evidence-strategy director needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in inspection-readiness findings at a CMO, then the action for RWE evidence-strategy director - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Missing page in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite